Annovis Bio

Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. She was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group. Additionally, Dr. Maccecchini was the founder and CEO of Symphony Pharmaceuticals/Annovis, a biotech company that was sold in 2001 to Transgenomic. She served as general manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt. Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology;her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.

Mr. McGroarty has been the Chief Financial Officer of Annovis Bio, Inc., since April 2019. Prior to joining Annovis, Mr. McGroarty served as Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc. from 2013 to 2018.

Mr. McGroarty joined Safeguard Scientifics in 2005 as Vice President and Corporate Controller subsequently became Vice President – Finance and Corporate Controller, and served as Senior Vice President – Finance from 2012 to 2013.

Mr. McGroarty served as Interim Controller of Cephalon, Inc. in 2005; Vice President-Financial Planning & Analysis and previously Assistant Controller at Exide Technologies from 2002 to 2005; and, previously, with PricewaterhouseCoopers from 1991 to 2001.

Mr. McGroarty earned his Bachelor’s degree from The Pennsylvania State University and his MBA from The Wharton School of The University of Pennsylvania.